Drug intelligence / Profile preview

PGT121 + VRC07-523LS

Development stage: Unknown
Lead developer: International AIDS Vaccine Initiative
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous, Intramuscular

Overview

PGT121 + VRC07-523LS is a combination of two broadly neutralizing monoclonal antibodies (bNAbs) targeting different epitopes on the HIV-1 envelope protein. VRC07-523LS targets the CD4 binding site and was engineered for increased neutralization breadth and half-life (approximately 29-45 days). PGT121 targets the V3 glycan region and has a half-life of approximately 20 days. This combination provides complementary coverage against diverse HIV strains and is being developed for both HIV prevention and treatment strategies.

Targets

Human immunodeficiency virus 1 envelope glycoprotein gp120 V3-base glycan epitopegp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)

Beyond the preview

Go deeper on PGT121 + VRC07-523LS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGT121 + VRC07-523LS.

Explore the full profile